About Opentopia
Opentopia Directory Encyclopedia Tools

Thiomersal controversy

Encyclopedia : T : TH : THI : Thiomersal controversy

In recent years, it has been suggested that thiomersal in childhood vaccines could contribute to or cause neurodevelopmental disorders in children (most notably autism, as well as other disorders within the Pervasive Developmental Disorder (PDD) category and Attention Deficit Hyperactivity Disorder (ADHD)). The basis for this claim is the introduction of an organic mercury compound — ethylmercury — straight into the tissue of young children. Some opponents of the use of thiomersal argue that this could have an effect on young children, who may have undeveloped immune and neurological systems that would be affected in some way.

There is concern on both sides of the debate in regards to motivating factors. Those who denounce thimerosal suspect that government agencies and pharmaceutical companies are denying a connection for fear of financial liability and the creation of mistrust in vaccinations. Extraction of information from FDA site plus additional information & discussion> Proceedings of ongoing claim in Washington DC, USA Those who deny a connection between thimerosal and neurological disorders have charged thimerosal's critics as being medically and scientifically unqualified, emotionally distraught, or interested in pursuing litigation.

Contents

Basis for concerns

The Food and Drug Administration (FDA) Modernization Act of 1997 called for a review and risk assessment of all mercury-containing food and drugs.[link] Vaccine manufacturers responded to FDA requests for December 1998 and April 1999 to provide detailed information about the thimerosal content of their preparations. From the early 1970s until present day, the number of vaccines regularly received by children in the US before the age of four has risen from two or three to up to twenty-two.

Through its Center for Biologics Evaluation and Research (CBER), the FDA studied the results and found regularly vaccinated young children were injected with up to 187.5 mcg of ethylmercury by the time they were six months old. When trying to assess whether this dosage was likely to cause damage, the CBER could not find guidelines for ethylmercury.

The FDA recognized that some children who receive thimerosal-containing vaccines may have, over time, exceeded federal guidelines for bolus (single-dose) mercury exposure, based on methylmercury (but not ethylmercury) studies. The United States Public Health Service (PHS), American Academy of Pediatrics (AAP) and vaccine manufacturers agreed that thimerosal-containing vaccines should be removed as soon as possible because of the potential risk of adverse effects from mercury exposure.[link] Similar conclusions were reached by the European Medicines Agency.[link] In June of 1999, Dr. Neal A. Halsey, director of the Johns Hopkins University Institute for Vaccine Safety, Former Chairman of the American Academy of Pediatrics and a vocal supporter of the vaccination policy, was apprised of the results of the CBER study. Dr. Halsey enlisted Dr. Walter Orenstein, the director of the Centers for Disease Control's (CDC) National Immunization Program for advice. Along with leaders of the American Academy of Pediatrics, the group advised a cautious stance by informing physicians about the findings.[link] Negotiations within the AAP resulted in a press release calling for a delay of Hepatitis B vaccines under certain circumstances.[link] Due to the concerns that were raised, the Centers for Disease Control and the National Institutes of Health (NIH) asked the National Academy of Science's (NAS) Institute of Medicine (IOM) to establish an independent expert committee to review hypotheses about existing and emerging immunization safety concerns. In 2001 the IOM committee concluded that the hypothesis was biologically plausible; however, the evidence was inadequate to accept or reject a causal relationship between thimerosal exposures from childhood vaccines and neurodevelopmental disorders.[link][link][link][link] The IOM panel reconvened in 2004 and concluded the evidence that was presented favored a rejection of a causal relationship between thimerosal-containing vaccines and autism; and that hypotheses generated to date concerning a biological mechanism for such causality are theoretical only. The IOM went on to recommend the termination of additional research into the subject, stating clearly that, "Further research to find the cause of autism should be directed toward other lines of inquiry". The IOM committee chair stated, "Available funding for autism research should be channeled to the most promising areas, of which the link with vaccines does not appear to be one."[link][link] Some advocacy groups felt the IOM's 2004 decision was premature.[link][link] The Journal of American Physicians and Surgeons Volume 11 Number 1 Spring 2006 published a study indicating a corresponding downward trend for neurological disorders in children matching the decline of Thimerosal use in vaccines,[link] a journal not listed in the major journal databases of PubMed and Web-of-Science.

State of the controversy

Below are some of the arguments raised against including thiomersal in vaccines:

Thimerosal is used in multi-dose vaccine vials in effort to reduce the likelihood of microbial contamination. The need for bacteriostatic agents like thimerosal can be avoided by using a single dose vial. Packaging as single-dose vials increases the cost of manufacturing, shipping, storing, and delivering vaccines and is blamed, at least in part, for intermittent shortages of vaccines in recent years.[link] It has been assumed thimerosal has been removed from vaccines since 1999. However, some pharmaceutical companies did not receive regulatory approval for their thimerosal-free infant vaccines until 2003. Infant vaccines produced before 2003 may contain up to 25μg of thimerosal. These vaccines have not been recalled and it is possible they are still in use. They will not expire until 2006 at the earliest, 2008 at the latest.[link][link] Currently[[Citing sources citation needed]] the adolescent and adult tetanus vaccine and certain influenza[[Citing sources citation needed]] vaccines still contain thimerosal.

Legal Aspect to the Controversy in the United States

In 1986, the National Childhood Vaccine Injury Act established a no-fault system for litigating claims against vaccine manufacturers. Under this law, all claims against Vaccine manufacturers could not be heard in state or federal court, but had to be heard rather in the U.S Court of Federal Claims. This court, often referred to as the “vaccine court,” hears cases without juries and awards damages that typically are far below damage awards rendered in other courts. The damage amounts are often insufficient to compensate severely injured children.

In 2001, epidemiologists from the Centers for disease control and prevention reported that thiomersal was linked to a dramatic rise in the number of cases of reported childhood autism. Since that announcement, over 4,000 law suits have been filed by the parents and guardians of afflicted children. Regardless, until March 2006, these plaintiffs were forced to litigate in the so called “vaccine court” with its predictably low damage recovery.

In March of 2006, the U.S. 5th Circuit Court of Appeals ruled that plaintiffs suing three manufactures of thiomersal could bypass the U.S Court of Federal Claims (the so called “vaccine court”) and litigate in either state or federal court utilizing the ordinary channels for recovery in tort. Holder v. Abbott Laboratories Inc., 444 F.3d 383. The ruling is significant since this is the first instance where a federal appeals court has held that a suit of this nature may bypass the “vaccine court.” The 5th circuit court reached its conclusion by first looking to the statutory intent of the 1986 National Childhood Vaccine Injury Act and determining that the intent of the statute was to protect the manufacturers of vaccines. In this case, thiomersal is not a vaccine, but a preservative and as such, the manufactures of this preservative cannot share in the protection afforded by the no-fault regime ushered in by the National Childhood Vaccine Injury Act.

See also

External links

Links to news sites or weblogs that have an interest in the thimerosal controversy. The list is broken into two groups, those that espouse the theory that thimerosal causes neurological disorders and those that reject the theory as unlikely.

News item

Accept theory

Reject theory

References

Vaccination/Vaccine (and Immunization, Inoculation. See also List of vaccine topics and Epidemiology)
Development: Models - Timeline - Toxoid - Trial

Administration: ACIP - GAVI - VAERS - Vaccination schedule - VSD

Specific vaccines: Anthrax - BCG - Cancer - DPT - Flu - HIV - HPV - MMR - Pneumonia - Polio - Smallpox

Controversy: A-CHAMP - Anti-vaccinationists - NCVIA - Pox party - Safe Minds - Simpsonwood - Thimerosal controversy - Vaccine injury

 

From Wikipedia, the Free Encyclopedia. Original article here. Support Wikipedia by contributing or donating.
All text is available under the terms of the GNU Free Documentation License See Wikipedia Copyrights for details.

Search Titles
0123456789
ABCDEFGHIJ
KLMNOPQRST
UVWXYZ?

E-mail this article to:

Personal Message: